Janusmed

Teratology service

Region Stockholm, which provides the service and its technical platform. · Sweden

Visit the source site · Audited 2026-10-14

Who pays for it

Region Stockholm provides and operates Janusmed, but the reviewed pages give no service budget, funding shares, or specific industry contribution; the amount is unverified.

Status: Supporting

Janusmed describes itself as manufacturer-independent, but its full budget and author disclosures were not verified and some register data are not adjusted for background differences. SafeMomma uses it as an additional check, not as a stand-alone basis for important claims.

How SafeMomma uses it

Used as an additional pregnancy check, with its written limits considered rather than relying on a color category alone.

The audit

Who controls it: Region Stockholm provides Janusmed. Fetal-impact pages name medical and scientific authors and a reference group, while the regional health administration supplies the platform and distribution.
Money: The reviewed pages identify Region Stockholm as provider but publish no Janusmed fetal-impact budget, funding shares, or specific industry contribution. No product ads or manufacturer sponsorship were identified; the amount is unverified, not zero.
Conflict rules: The review found no public author-conflict policy or author-by-author disclosures for fetal-impact entries. Manufacturer independence and named reviewers do not replace individual disclosures.
Method: Assessments combine Swedish register data and literature searches. Janusmed says its register figures are not adjusted for background differences, so a risk increase may reflect other factors; prescription data for exposures from week 13 to delivery were added from early 2025.
Dates on its pages: Janusmed says most fetal-impact pages are updated every two years and some selected pages every five years; its methods page was updated 26 September 2025.
Political exposure: Janusmed is a Region Stockholm public service, so staffing and budget depend on public decisions. No 2015–2026 political rewrite, pressured page removal, or interference with a fetal-impact conclusion was identified in the reviewed sources.
Money exposure: No pharmaceutical-company funding or product sponsor was identified in the reviewed fetal-impact pages. Use of commercial or professional reference sources is not evidence of sponsorship; the full budget and author disclosure process remain unverified.
Track record: Janusmed was not tested as a source in the five b1–b5 backtests. The review found no source-specific major correction or retraction; its prominent warning that register data are not adjusted helps prevent readers from treating an association as cause.

Where this comes from

Incentive exposure describes pressure from money or politics, not whether the source is right. Funding alone does not show influence.

← Back to Our sources